Prostate Cancer: PSA Change May Be Key to Risk
Researchers Say Tracking PSA Changes Indicates Who's at Risk of Dying When Cancer Returns
WebMD News Archive
July 26, 2005 -- What's the risk of dying when prostate cancer comes back
after treatment? Two new studies point to who's at high risk and who isn't.
A crucial difference, the two new studies suggest, is how fast blood levels
of prostate-specific antigen (PSA) go up.
Anthony V. D'Amico, MD, PhD, chief of genitourinary radiation oncology at
Brigham and Women's Hospital and Dana-Farber Cancer Institute, led a study of
358 men who underwent radiation therapy. His team looked at whether
prediagnosis changes in PSA predicted a man's risk of dying from prostate
cancer. The findings confirmed the results of an
"The best use of PSA is not to look at the number but to look at the
trend over time," D'Amico tells WebMD.
Stephen J. Freedland, MD, clinical instructor in urology at Johns Hopkins
University, led a team that gathered data on 379 men who underwent prostate
surgery but had their cancer come back.
"These studies show that looking at changes in PSA are more important
than a single value," Freedland tells WebMD. "One PSA result is like
looking at a snapshot of a horse race and trying to determine who will win.
Looking at snapshots over time gives you a better idea."
Both studies appear in the July 27 issue of The Journal of the American
PSA is a chemical marker on the outside of prostate cells. As prostate
cancer cells increase in number, blood PSA levels rise.
But PSA levels in and of themselves aren't a reliable indicator of cancer.
Blood levels of PSA go up for other reasons besides cancer. And very deadly
prostate cancers can occur even at low PSA levels.
"There has been controversy over what is the best use of PSA as a
screening tool and what is the best use of the test as a tool to guide
treatment," D'Amico says.
Instead of simply testing once for PSA and deciding that it is
"high" or "normal," D'Amico says it appears to be more useful
to test at regular intervals. This gives a reading on PSA change -- what
doctors call PSA velocity.
"Our study shows that men who experience a two-point rise in PSA in the
year preceding a diagnosis of prostate cancer -- despite a low level of PSA and
despite a biopsy showing a supposedly 'favorable' prostate cancer -- have more
aggressive cancer and need more aggressive treatment to cure it."
Men whose PSA levels rose more than two points in a year had a 12-fold
higher risk of dying from prostate cancer than men whose PSA levels rose less
"The median survival for rapid risers is only six years, and that is
very short for prostate cancer," D'Amico says. "The bottom line for
patients is this: Get a PSA test annually and know the result. Because even if
your doctor isn't looking at year-to-year change, at least you can. We
recommend getting a baseline PSA test at age 35, especially for men whose dads
had prostate cancer."